CN105815782A - 青稞减肥餐 - Google Patents
青稞减肥餐 Download PDFInfo
- Publication number
- CN105815782A CN105815782A CN201610154803.1A CN201610154803A CN105815782A CN 105815782 A CN105815782 A CN 105815782A CN 201610154803 A CN201610154803 A CN 201610154803A CN 105815782 A CN105815782 A CN 105815782A
- Authority
- CN
- China
- Prior art keywords
- fat
- blood
- highland barley
- reducing
- kilogram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000007340 Hordeum vulgare Nutrition 0.000 title claims abstract description 20
- 235000005911 diet Nutrition 0.000 title claims abstract description 12
- 230000037213 diet Effects 0.000 title claims abstract description 11
- 240000005979 Hordeum vulgare Species 0.000 title claims 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 30
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 30
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 30
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 30
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 30
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 30
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 30
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 30
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 29
- 239000000661 sodium alginate Substances 0.000 claims abstract description 29
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 29
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 28
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 25
- 235000010445 lecithin Nutrition 0.000 claims abstract description 25
- 239000000787 lecithin Substances 0.000 claims abstract description 25
- 229940067606 lecithin Drugs 0.000 claims abstract description 25
- 229920000294 Resistant starch Polymers 0.000 claims abstract description 20
- 235000021254 resistant starch Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 238000004806 packaging method and process Methods 0.000 claims abstract description 5
- 210000000582 semen Anatomy 0.000 claims description 35
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 38
- 239000008280 blood Substances 0.000 abstract description 38
- 241000209219 Hordeum Species 0.000 abstract description 19
- 230000036772 blood pressure Effects 0.000 abstract description 14
- 230000036039 immunity Effects 0.000 abstract description 14
- 241000196324 Embryophyta Species 0.000 abstract description 9
- 239000003053 toxin Substances 0.000 abstract description 8
- 231100000765 toxin Toxicity 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 5
- 235000013376 functional food Nutrition 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 230000009977 dual effect Effects 0.000 abstract description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 43
- 235000019197 fats Nutrition 0.000 description 41
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 40
- 238000011160 research Methods 0.000 description 28
- 230000006870 function Effects 0.000 description 22
- 238000010521 absorption reaction Methods 0.000 description 17
- 230000000968 intestinal effect Effects 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 230000001603 reducing effect Effects 0.000 description 12
- 229920002307 Dextran Polymers 0.000 description 10
- 235000013325 dietary fiber Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 7
- 235000019260 propionic acid Nutrition 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000000711 cancerogenic effect Effects 0.000 description 6
- 231100000357 carcinogen Toxicity 0.000 description 6
- 239000003183 carcinogenic agent Substances 0.000 description 6
- 229910001385 heavy metal Inorganic materials 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000036186 satiety Effects 0.000 description 6
- 235000019627 satiety Nutrition 0.000 description 6
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 5
- 229920002498 Beta-glucan Polymers 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229930014669 anthocyanidin Natural products 0.000 description 3
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 3
- 235000008758 anthocyanidins Nutrition 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000031891 intestinal absorption Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 235000021407 appetite control Nutrition 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 230000035568 catharsis Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000006362 insulin response pathway Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- -1 sodium alginate compound Chemical class 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- UDIODXADSSQKTM-GUHNCMMLSA-N (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;(7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5- Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 UDIODXADSSQKTM-GUHNCMMLSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108010072661 Angiotensin Amide Proteins 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101000929923 Caenorhabditis elegans Acetylcholinesterase 1 Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- JXRNMQDTJAQLAQ-UHFFFAOYSA-N Heptadecatetraen Natural products CCC=CCC=CCC=CCCCCCC=C JXRNMQDTJAQLAQ-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 235000021170 buffet Nutrition 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- YTJJRAWFHJBAMT-UHFFFAOYSA-N depside Natural products OC(=O)CC1=C(O)C=C(O)C=C1OC(=O)C1=CC=C(O)C(O)=C1 YTJJRAWFHJBAMT-UHFFFAOYSA-N 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical group OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
青稞减肥餐本发明属于功能食品,尤以青藏高原天然无污染优质两用植物青稞提取物(黑青稞)、海藻酸钠、抗性淀粉、绿原酸、丙酸酯、卵磷脂等原料制成的功能食品。该产品具有提高免疫力、减肥、降血压、降血脂、降血糖、通便排毒、抗癌等功效,该产品的制作工艺:调配混合、搅拌、检验、包装成为正式产品。
Description
一、技术领域:本发明属功能食品,尤以青藏高原天然无污染优质药食两用为原料青稞提取物(黑青稞)、海藻酸钠、抗性淀粉、绿原酸、丙酸酯、卵磷脂等原料,采取现代先进工艺加工而成的功能食品。
二、背景技术:本发明以青稞提取物(黑青稞)、海藻酸钠、抗性淀粉、绿原酸、丙酸酯、卵磷脂等原料制成的功能食品。该产品具有提高免疫力、减肥、降血压、降血脂、降血糖、通便排毒、抗癌等功效。目前市场上还没有同类产品,创新研发该产品可为给减肥瘦身的人群提供了一种新产品。该产品以纯天然药食两用植物和营养品和生物活性成分为原料制成的减肥餐、纯度高、吸收好、生物活性强、无任何副作用、服用方便、效果明显,适应于各年龄段的减肥人群服用。
三、发明内容:肥胖是一种营养代谢综合失调性疾病和低度全身慢性炎症。研究发现,肥胖病因相当复杂,不仅有明显的遗传性,还与饮食和运动密切相关。在今天肥胖已成为一个社会严重的公共卫生问题。世界卫生组织(WHO)认为,肥胖与艾滋病、吸毒、凶酒并列为世界四大社会问题,医学界称之为人类死亡率高的癌症,冠心病、糖尿病、高血压、高血脂、心脑血管疾病都与肥胖直接有关。随着我国经济的快速发展,人民生活水平的不断提高,肥胖正在成为一个关注的流行病。根据世界卫生组织的统计数学显示,全球超重人数超过10亿多,有3亿多人严重肥胖,而发展中国家的肥胖比例大幅增加。在我国根据卫生部、科技部和国家统计局公布的营养与健康状况调查结果显示,我国13亿人口中有2亿人超重,特别是儿童超重迅速增长。预计今后肥胖患病率还将会有较大幅度的增长,肥胖会给国民健康造成严重的威胁,也会给个人和社会带来沉重的经济负担。
四、原料配方:青稞提取物(黑青稞)10-100千克、海藻酸钠5-10千克、抗性淀粉10-20千克、绿原酸2-8千克、丙酸酯1-5千克、卵磷脂4-7千克为原料。
五、技术方案:
(一)青稞(barley),又叫大麦、元麦等。青稞为禾本科大麦属谷物成熟种子。性平、味咸、归脾、胃、大肠经。具有健脾养胃、益气止泻、壮精益力、除湿发汗的功效。适应脾胃气虚,倦怠无力,腹泻便唐者食用。现代医药研究表明,青稞具有降血脂、降低胆固醇、降血糖、降血压、预防心血管疾病、减肥、通便、抗癌、增强免疫力,明目护眼等作用。
化学成分:青稞含有蛋白质、脂肪、碳水化合物、膳食纤维、花青素、多种维生素、多种矿物质和微量元素等成分。
生理功能:1、增强免疫力:动物实验证明,青稞中β-葡聚糖具有增强免疫力功能。用青稞β-葡聚糖进行了大鼠腹腔巨噬细胞产生白介素(IL-1)及培养脾脏细胞诱导产生IL-2,干扰素(INF-γ)和IL-4的试验,结果证实,青稞β-葡聚糖能起到诱导作用,同时食用青稞β-葡聚糖对于已感染金黄色葡萄球菌有延长寿命的效果。研究认为,青稞β-葡聚糖能增强免疫功能的作用机理是通过刺激细胞SEB系统,使机体产生INF-γ,从而增强机体免疫力。
2、降血压:研究认为,青稞除了具有降低胆固醇和降血糖的作用外,青稞还有降血压的功效。据报道有人对18名男女轻度高血压症和高胰岛素血症的患者,用富β-葡聚糖青稞全粒粉早餐进行试验,结果显示,摄取青稞早餐组患者收缩期血压明显降低和扩张期血压明显降低,观察还发现,青稞早餐摄取组患者的总胆固醇、LDL(有害胆固醇)和血清葡萄糖也明显下降。试验结果证明,摄取青稞β-葡聚糖的食物可明显减少高血压治疗药和用量,改善了对血压的控制,具有治疗和预防高血压的作用。另外,分析还表明,青稞含有的花青素具有消炎、抗氧化、改善微循环和改善血管弹性,因此,具有降血压的作用,其作用相当于血管紧张素酶抑制剂(ACE-1)。另据报道,青稞、β-葡聚糖在人体内不能消化吸收,具有双岐杆菌的增值作用,能强化细胞功能,防止机体被感染和修复被破坏的组织。人们由于物理的原因或精神压力,导致免疫力降低,在辐射环境下或不合理的膳食均会使免疫力受损,青稞β-葡聚糖能促使提高抵抗力,减少传染疾病的侵害,有明显增强免疫力和抗癌作用。另外,还有降低电脑荧光屏辐射对人体造成的危害。
3、降血糖:青稞β-葡聚糖能提高食物消化物的黏性,从而延迟葡萄糖的吸收,达到降血糖的作用。动物试验显示,用富含青稞β-葡聚糖的基料饲喂高血糖模型大鼠,8周后大鼠血中血糖比高血糖对照组降低58.9%,餐后30分钟血溏升高值分别比正常对照组和高血糖对照组降低62.7%和76.7%,青稞β-葡聚糖具有调节血糖的作用。试验结果还证明,青稞β-葡聚糖可调节胰岛素水平,预防和辅助治疗由糖耐量而引起的糖尿病等症。其作用机理是青稞中β-葡聚糖在肠道吸收后膨胀增加容积,降低能量密度,抑制淀粉酶活性,干扰糖的代谢,延缓了人体对葡萄糖的吸收,从而降低空腹血糖和餐后血糖。
4、降血脂和胆固醇:青稞给动物喂食能明显对抗高脂饲料所致的动脉硬化,可使活性增加,血清胆固醇降低,显著升高高密度脂蛋白。青稞还能降低血清胆固醇和甘油三酯的含量,同时还能抑制饮食诱导肝组织胆固醇,甘油三酯、过氧化脂质含量增加。因此,具有良好的降血脂和胆固醇的作用。青稞含有大量的水溶性膳食纤维物质和β-葡聚糖,在进入肠道后会吸收大量水分,并形成胶状物质,能阻止肠壁细胞吸收脂质,起到降血脂的作用。
5、减肥:研究表明,青稞含有大量膳食纤维的食品可有效减少人体的饥饿感,从而达到控制饮食和体重的目的。研究发现,青稞是含有丰富膳食纤维的食品,可控制能量的摄入和对人体新陈代谢以及可调节食欲的激素产生有益影响,因此,青稞可有效控制人体食欲,起到减肥的作用。另外,青稞中的膳食纤维能与部分脂肪酸结合,使脂肪酸通过消化道时不能被吸收,对肥胖病人起到减轻体重的作用。
6、排毒:研究表明:青稞中膳食纤维对汞、砷、镉和其他重金属具有清除作用和对有机物具有吸附螯合作用。青稞可螯合吸附胆固醇,胆汁酸之类的有机物,抑制人体吸收,还可吸附肠道内的有毒物质(内源性毒素),化学药品(外源性毒物),并将其排除体外。
7、防止便秘:青稞中的丰富纤维能使食物在肠道内通过的时间缩短,使大肠内的粪便量相对增加,有助于大肠的蠕动,使粪便易于排出,从而达到防治便秘的作用。
8、预防大肠癌:研究发现,大肠癌的发生主要与毒素和致癌物在肠道内长期积累,与肠黏膜长期接触等因素有关,从而容易发生大肠癌。而青稞含有丰富的腾食纤维能吸附大肠中的致癌物质,使致癌物质浓度相对减少。加之膳食纤维有刺激肠道蠕动的作用,加快排空肠道毒素和致癌物,缩短了食物在大肠的停留时间,使致癌物质及时随大便排出体外。此外,青稞还可改善大肠的益生菌,增加肠内抗氧化剂,因此,有防治大肠癌的作用。
另外,青稞还具有增强免疫力,预防心脑血管疾病、抗缺氧、延缓衰老,清汤等作用。青稞含有的花青素还有护眼明目的作用。
(二)、海藻酸钠(satiumalginateSA)又名褐藻胶。是从褐藻植物中提取的一种天然高分子多糖,也是一种水溶性膳食纤维,具有多种生理学独特功能。有降血压、降血糖、调节血脂,增加饱腹感、减肥、增强免疫力、抗辐射、整肠、保护胃肠道、防癌抗癌,排出重金属等功能。
生理功能:海藻酸钠
1、降血脂:海藻酸钠具有降低血清总胆固醇和甘油三酯,升高高密度脂蛋白,降低低密度脂蛋白,从而防治动脉硬化。动物实验表明,海藻酸钠中高剂量组的总胆固醇及总甘油三酯含量与高脂对照组比较,前者降低了10.6%、15%,后者降低了19.8%和27.1%,低、中、高实验组的高密度脂蛋白胆固醇与高脂对照组比较,分别升高17.5%、33.7%、51%。有报道对31位高血脂症成人患者进行口服海藻酸钠,30天后检测,结果显示,血清总胆固醇、甘油三酯和低密度脂蛋白明显下降。这是因为海藻酸钠能抑制胆固醇在小肠内吸收并促进排出,从而使胆固醇和甘油三酯下降。
2、降血压:现代医学研究认为,血压升高与人体内氯离子含量升高有关,而海藻酸钠能与氯离子结合,并将其排出体外,使体内氯离子水平降低,使血管紧张素II形成减少,体内缓激肽增加,血管扩张起到降压作用。
3、降血糖:胰岛素的活性与人体内的PH值有关,若PH值上升0.1,则胰岛素的活性上升约30%。海藻酸钠不仅能效调节人体内酸碱平衡,提高海藻酸钠的活性和胰岛素的敏感性,从而起到降血糖的作用。
4、强化肝脏功能:长期饮酒,可引起酒精性脂肪肝和肝硬化。肝脏是人体最重要的代谢器管,同时肝脏还能分解、代谢人体内的酒精等有毒物质。研究发现,海藻酸钠能增强肝脏的功能,促进人体毒素分解并促进排泄,防止脂肪肝和病毒性肝炎发生。
5、降脂减肥:海藻酸钠具有独特的降脂减肥作用,其减肥重要作用是抑制食欲。海藻酸钠属于可溶性膳食纤维的特性,具有很强的吸水性,使人产生饱腹感,从而减少食物的摄入量,来减少动物脂肪和胆固醇的吸收,达到减肥的作用。据国外报道,海藻酸钠化合物能阻止身体对脂肪的吸收,对减肥具有一定的功效。英国纽卡斯尔大学研究发现,海藻酸钠能有效抑制人体对脂肪的消化与吸收。当海藻酸钠含量上升4倍之后,人体对抗脂肪吸收的能力提高75%。
6、吸附重金属,海藻酸钠其分子中存在有羟基、氨基等化学基团,因而对许多重金属离子具有很好的螯合作用。不仅能有效吸附或捕集重金属离子,而且还能抑制铅等重金属在肠道内的吸收,并促进排出体外。
7、增强免疫力:海藻酸钠能明显增强小鼠腹腔巨噬细胞的吞噬功能,并有增强体液免疫功能的作用。研究表明,海藻酸钠能明显提高小鼠红细胞C36受体花环抑制率和红细胞C36受体花环促进率,降低红细胞免疫复合物花环率和血清中红细胞C36受体花环抑制率,结果证实,海藻酸钠对小鼠的红细胞免疫功能有明显的促进作用。
8、抗辐射:海藻酸钠对辐射具有明显的防护作用,它能使接受急性辐射的小鼠存活率提高63%,还能显著减轻小鼠骨髓细胞辐射遗传的损伤,能促进造血干细胞等增殖和分化,激活细胞内多条信号传递系统,提高对辐射的耐受力,促进造血系统受辐射损伤后的恢复。
9、抗菌:海藻酸钠在试管内同心性毛癣菌、铁锈色小芽胞癣菌,腹股沟表皮癣菌,红色表皮癣菌等皮肤真菌有明显的抑制作用。对枯草杆菌也有一定的抑制作用。
10、抗肿瘤:海藻酸钠能抑制小鼠S180肉瘤的生长。对小鼠巨噬细胞有较强的免疫调节作用,这是抑制肿瘤的机制之一。此外,海藻酸钠还具有降血压、降血脂、降血糖、抗病毒等功能,治疗心血管病及肠道系统疾病。
(三)抗性淀粉(resistantstarch),又称抗酶解淀粉及难消化淀粉。是存在于许多天然食物中的一种类似膳食纤维的化合物。抗性淀粉是利用物理、化学或酶法处理后,改变了淀粉的天然性质,增加了新的特性和保健功能。这种经过二次加工,改变了特性的淀粉为抗性淀粉。科学研究表明,抗性淀粉具有减肥瘦身、降血脂、防治心血管病、降血糖、改善肠道功能、通便、抗癌防癌等功能。
生理功能:1、减肥瘦身:抗性淀粉本身几乎不合热量,可减少热量的摄入,而且可减少体内脂肪的吸收与脂肪酸的合成,增加脂肪的排汇,还可控制食欲和巨量营养素平衡,并有持久的饱腹感,从而达到减肥瘦身的目的。
2、降血脂:动物实验证明,抗性定粉能降低血浆中低密度脂蛋白胆固醇和甘油三酯含量,其作用是缓解结场上皮萎缩,增加胆固醇和胆酸的排出,并减少脂质的吸收和脂肪酸的合成,从而降低血液和肝脏中的脂肪含量。
3、降血糖和防治糖尿病:研究发现,碳水化合物又称多糖,食用后要在体内酶被胃酸和酶消化分解为单糖一葡萄糖以后才能吸收并进入血液,抗性淀粉可抵抗酶的分解,在体内消化吸收,具有较低的胰岛素反应,可调节和控制血糖水平,有助于维持正常的血糖。另外,抗性淀粉还具有防治糖尿病的作用,能有效降低血糖生成指数和胰岛素反应,尤其对2型糖尿病餐后血糖上升具有显著的作用,因此,抗性淀粉能有效控制糖尿病。
4、改善肠道功能:抗性淀粉可被大肠中有益细菌发酵产生大量的短链脂肪酸丁酸、丙酸、乙酸等。可调节肠道PH值,改善有益菌的繁殖环境,促进益生菌的生长繁殖,使有益菌群迅速扩大,有效抑制腐败菌生长,防止肠道黏膜萎缩和保持肠黏膜屏障功能。因此,抗性淀粉具有改善肠道功能。
5、通便:抗性淀粉可增加粪便体积,刺激肠道蠕动,加速排便频率,使粪便及有害物质及时排出体外。
6、防癌抗癌:研究显示,抗性淀粉在肠道不被消化作为肠道的菌群营养源,通过微生物发酵生成丁酸等短链脂肪酸,降低肠道及粪便PH,促进肠道健康,减少肠内腐败菌产生的胺类、硫化氢、吲哚、亚硝胺、内毒素等致癌物质的产生,进而降低患肠癌的风险,并能抑制肿瘤细胞。
(四)绿原酸(ChlorogenicacidCA),绿原酸是广泛存在于多种天然植物中,是由咖啡酸和奎尼酸等生成的缩酚酸,是植物体在有氧呼吸过程中经莽草酸途经产生的一种苯丙素类化合物。现代科学研究表明,绿原酸具有广泛的生物学功能,是一种重要的生物活性物质,具有减肥降脂、降血压、降血脂、防治糖尿病、抗菌、抗病毒、保肝利胆、清除自由基、增高白血球、抗肿瘤和兴奋中枢神经系统等作用。
生理作用:1、降脂减肥:研究表明,绿原酸具有显著的减肥作用。分析认为,绿原酸在肝脏中可以起产生糖的作用,当人体在运动和采用食物疗法消耗体内糖分时,肝脏就会自动利用肌肉中的某种合成糖,而绿酸与之相关联的产生葡萄糖-6-磷酸酯酶的活性作用,是肝脏不能进行体内糖合成过程,这就是绿原酸阻碍饮食疗法减肥塑身产品不产生反弹的过程和原理。另外,绿原酸还具有延缓脂肪吸收的效能来阻碍脂肪分解酶的活性,燃烧脂肪,具有减肥和阻止体内脂肪积聚的作用。据国外报道,发现咖啡中的绿原酸具有明显的减肥效果。研究人员以高脂饮食喂养小鼠长达15周时,同时每周给小鼠注射两次绿原酸,结果显示,绿原酸不仅可以控制小鼠体重的增加,防止脂肪在肝脏堆积。
2、防治糖尿病:研究表明,绿原酸是一种很强的天然抗氧化剂,对参与小肠内等糖形成的酶有抑制作用,抑制这种酶是控制高血糖浓度或高血糖症的有效方法。另外,绿原酸还具有降低胰岛素抵抗和降低胰岛素值,同时还可促进葡萄糖代谢,控制餐后血糖上升,降低血糖耐量受损。
3、抗菌消炎:研究发现,绿原酸有较强的抗菌消炎作用。绿原酸具有很强的抗氧化功能,可以减少炎症,大量的研究数据证明,与肥胖相关的疾病是由于慢性炎症引起的,因为绿原酸具有强大的抗炎作用,能抵抗肥胖症慢性炎症造成的负面影响。
4、抗氧化:绿原酸是一种较强的多酚类抗氧化物质,其抗氧化效果优于阿魏酸、咖啡酸、维生素C和维生素E,可有效消除羟基自由基和超氧阴离子自由基等自由基的活性,从而保护组织免受自由基的氧化作用损害。
5、保护肝脏:研究显示,绿原酸具有很强的保护肝脏作用。据国外报道,研究人员对5942例成年患有病毒性肝炎和酒精性肝炎的患者进行研究,这些人中有78.7%的患者血清丙氨酸转氨酶(ALT)水平高于正常值,21.2%的患者ALT水平高于正常值上限的2倍以上。研究人员给这些患者每天服用一定量的绿原酸,结果发现,服用绿原酸的患者明显降低了ALT水平,随着绿原酸服用量的相对增加,而患者ALT水平降低效果越明显,与不服用绿原酸的患者相比,服用绿原酸的患者ALT水平下降50%。其机理是绿原酸具有修复肝细胞的功效作用。
另外,绿原酸还具有降血压、降血脂、防治心血管病、清除自由基、抗衰老、抗毒病、抗突变、抗肿瘤、增高白血球、清热解毒、养颜美容、解除烟酒等多种功能。
(五)丙酸脂减肥:研究表明,丙酸脂可以抑制人的胃口减少食量,增加饱腹感,起到减肥作用。据有关报道,肥胖者食用添加丙酸脂的食品,吃自助餐时的食量减少15%,研究认为,服用丙酸酯可以导致长时间饱腹感,防止过量的饮食。研究人员称丙酸酯可激发肠道产生可作用大脑的激素,从而使饱腹感来得更快,且持续时间更长。研究人员在实验过程中将志愿者分为两组,其中一组服用丙酸脂,另一组服用等量的天然多糖木香素作为对比组,结果显示,丙酸脂能有效防止饮食过量,而且还能减少肝脏和胃上的脂质。研究称,丙酸脂可以促进肠道激素的产生,从而控制食欲,以有效减肥。
(六)卵磷脂(lecithin),卵磷脂是由甘油、脂肪酸和胆碱组成的磷脂,是广泛存在于动植物和蛋黄之中的等动植物。磷脂是一类含磷酸根的类脂化合物的总称,是动植物中细胞膜、核膜、质体膜的基本成分和生命的基础物质之一。磷脂分为植物磷脂和动物磷脂。卵磷脂其结构和人体磷脂相同,具有促进新陈代谢,促进机体健康、智力发育、增强记忆力、降血脂、护肝、减肥和延缓衰老等功效。
药理功效:1、促进脂肪代谢,卵磷脂是代谢脂肪的活性物质,卵磷脂中的胆碱影响着脂肪的代谢,能促进脂肪代谢,从而改变人体脂肪的吸收与利用,缩短脂肪在人体内的滞留时间,起到促进脂肪代谢的减肥作用。
2、保护肝脏:卵磷脂是维持肝脏正常功能的必须营养物质。研究发现卵磷脂可以保护肝脏不受酒精的侵害,起到解酒的作用,从而有效防止酒精性肝硬化和脂肪肝等疾病的形成。进一步研究发现,卵磷脂不足是引起脂肪肝的一个重要的原因,脂肪在肝脏内蓄积会破坏肝细胞,易引发肝硬化。卵磷脂是合成脂蛋白所必需的物质,肝内脂肪则以脂蛋白形式转运到肝外,所以卵磷脂不但可以防止脂肪肝,而且还能促进肝细胞再生,防止肝硬化和恢复肝功能。
3、调节血脂:卵磷脂具有显著的降低血液中胆固醇、甘油三酯和低密度脂蛋白的作用,改善高脂血症。卵磷脂的分子结构中含有亲水的磷酸脂基团和亲油的脂肪酸基团,它可以使脂类物质和水结合在一起,起到乳化作用,能溶解血液中和血管壁上的脂溶性物质甘油三酯和胆固醇斑块,从而减少脂肪在血管壁上沉积,防止动脉硬化。另外研究发现,卵磷脂富含多不饱和脂肪酸,可以阻断小肠对胆固醇的吸收,促进胆固醇排泄。同时卵磷脂也是高密度脂蛋白(HDL的主要成分,在胆固醇的运送、分解、排泄过程起着“清道夫”的作用,因此卵磷脂具有降低血液中胆固醇和甘油三酯的作用,有效防止动脉粥硬化及高血脂引起的心脑血管疾病。
4、控制糖尿病:卵磷脂缺乏会降低人体胰脏细胞膜活性,使胰脏机能下降,无法分泌充足的胰岛素,不能有效地将血液中的葡萄糖运送到细胞中,会导致糖尿病。适量补充卵磷脂能明显改善糖尿病症状,很多糖尿病人甚至可不必再注射胰岛素,特别对糖尿病动脉硬化等并发症患者更为有效。
此外,卵磷脂还具有促进大脑发育,增强记忆,保护心脏健康,化解胆结石、美容、延缓衰老等功能。
综上所述,该产品具有提高免疫力、减肥、降血压、降血脂、降血糖、通便排毒、美容养颜、抗癌等功能。
六、制作工艺:1、调配混合:将配方中的所有原料按物理特性进行混合。
2、搅拌:将混合好的原料充分搅拌均匀。
3、检验包装:将搅拌均匀的原料,检验合格包装成为正式产品。
调配混合是将配方中的原料按物理特性进行混合工序。搅拌是将混合好的原料充分搅拌均匀的工序。检验包装是将搅拌均匀的原料检验合格包装成为正式产品。
七、质量标准:
1、理化指标:
2、服用方法:每日1-3次,每次1小包(50克)。
3、适用人群:男女老幼、儿童、青少年人群。
八、具体实施方式:
实施例:取青稞提取物(黑青稞)10-100千克、海藻酸钠5-10千克、抗性淀粉10-20千克、绿原酸2-8千克、丙酸酯1-5千克、卵磷脂4-7千克为原料,经过将以上原料调配混合,并充分搅拌均匀,检验合格,包装成为正式产品。
Claims (1)
1.青稞减肥餐的制作工艺,其特征为:青青稞提取物(黑青稞)10-100千克、海藻酸钠5-10千克、抗性淀粉10-20千克、绿原酸2-8千克、丙酸酯1-5千克、卵磷脂4-7千克为原料,经过将以上原料调配混合、充分搅拌均匀,检验合格,包装成为正式产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610154803.1A CN105815782A (zh) | 2016-03-18 | 2016-03-18 | 青稞减肥餐 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610154803.1A CN105815782A (zh) | 2016-03-18 | 2016-03-18 | 青稞减肥餐 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105815782A true CN105815782A (zh) | 2016-08-03 |
Family
ID=56525212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610154803.1A Pending CN105815782A (zh) | 2016-03-18 | 2016-03-18 | 青稞减肥餐 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105815782A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101884359A (zh) * | 2010-06-22 | 2010-11-17 | 苟春虎 | 五谷咖啡 |
CN105010976A (zh) * | 2015-08-03 | 2015-11-04 | 重庆赛福食品有限公司 | 一种减肥降糖营养粉及其制备方法 |
CN105077236A (zh) * | 2015-07-23 | 2015-11-25 | 汉济生物科技(武汉)有限公司 | 辅助降血糖的青稞复合特膳营养粉及其制备方法 |
-
2016
- 2016-03-18 CN CN201610154803.1A patent/CN105815782A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101884359A (zh) * | 2010-06-22 | 2010-11-17 | 苟春虎 | 五谷咖啡 |
CN105077236A (zh) * | 2015-07-23 | 2015-11-25 | 汉济生物科技(武汉)有限公司 | 辅助降血糖的青稞复合特膳营养粉及其制备方法 |
CN105010976A (zh) * | 2015-08-03 | 2015-11-04 | 重庆赛福食品有限公司 | 一种减肥降糖营养粉及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101606704B (zh) | 一种具有多种功能作用的膳食纤维食品 | |
CN101473953B (zh) | 净血排毒组合食品及其加工方法和应用 | |
CN104366480A (zh) | 一种减肥降脂营养代餐粉及其制备方法 | |
CN106174585A (zh) | 降血糖的组合物及降血糖的复合益生菌特膳食品 | |
CN105795468A (zh) | 一种具有减肥功效的组合物 | |
CN109221898A (zh) | 一种含低聚木糖的谷物粉及其制备方法和应用 | |
CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
CN105815514A (zh) | 藜麦减肥奶茶 | |
CN104605353A (zh) | 适用于手术后肿瘤患者食用的配方食品及其制备方法 | |
CA2316671A1 (en) | Nutritional products and method for treating and preventing cancer and other degenerative diseases | |
CN108402371A (zh) | 一种适合中老年便秘人群服用的益生元组合物 | |
CN105707378A (zh) | 黑青稞瘦身咖啡 | |
CN108713755A (zh) | 藜麦瘦身营养奶昔 | |
CN105613882A (zh) | 黑青稞降糖茶(奶茶) | |
CN1403017A (zh) | 富硒魔芋绿茶保健食品 | |
CN109965290B (zh) | 改善肠道菌群代餐粉及其应用 | |
CN114558038B (zh) | 一种用于减肥减脂的益生菌组合物及其制备方法和应用 | |
JP2004149471A (ja) | 血糖低下剤 | |
CN107712875A (zh) | 黑藜麦减肥代餐 | |
CN108371709A (zh) | 黑枸杞肿瘤康复基因酶 | |
CN105815782A (zh) | 青稞减肥餐 | |
CN105454601A (zh) | 黑青稞减肥茶(奶茶) | |
Lin et al. | Research Progress on the Immunomodulatory Effect of Trace Element Selenium and Its Effect on Immune-Related Diseases | |
CN107970437A (zh) | 虫草克癌基因肽 | |
CN110353198A (zh) | 一种适合航天员改善心脑血管的红曲双参固体制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160803 |
|
RJ01 | Rejection of invention patent application after publication |